PUBLIC COMPANY
save$MNPRMonopar Therapeutics
$MNPRWilmette, IL, USupdated 21d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
- phase1Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
- —MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
- phase1Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
- phase1Camsirubicin + Pegfilgrastim to Determine MTD in ASTS
- phase3Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.
Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Mar 31, 26tax coverRobinson Chandler · Chief Executive Officer1,972 sh
- Mar 31, 26tax coverCittadine Andrew · Chief Operating Officer1,571 sh
- Mar 31, 26option exerciseRobinson Chandler · Chief Executive Officer6,732 sh
- Mar 31, 26option exerciseCittadine Andrew · Chief Operating Officer3,514 sh
- Mar 31, 26option exerciseCittadine Andrew · Chief Operating Officer3,514 sh
- Mar 31, 26option exerciseRobinson Chandler · Chief Executive Officer6,732 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that